RVP · Retractable Technologies Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Domestic sales as a percentage of total revenues | 81.6% | the three months ended June 30, 2026 filing | +0.4% |
|
|
|||
| Domestic unit sales percentage of total unit sales | 70.3% | the three months ended June 30, 2026 filing | +2.0% |
|
|
|||
| Tariff expense | 46K | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVP
this stock
Retractable Technologies Inc
|
$17.40M | -24.5% | +15.8% | — | 0.2% |
|
ISRG
Intuitive Surgical Inc
|
$154.74B | -24.4% | +20.5% | 53.1 | 2.1% |
|
BDX
Becton Dickinson & Co
|
$52.93B | — | +8.2% | — | 3.6% |
|
MDLN
Medline Inc.
|
$46.62B | -15.9% | +11.5% | — | 4.0% |
|
RMD
Resmed Inc
|
$35.41B | +2.2% | +13.4% | 23.5 | 8.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVP | -2.0% | -16.4% | -7.8% | -15.9% | -24.6% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -2.5% | -17.1% | -15.4% | -17.3% | -37.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.